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Abstract
Background: Current clinical and histopathological criteria used to define the prognosis of
melanoma patients are inadequate for accurate prediction of clinical outcome. We investigated
whether genome screening by means of high-throughput gene microarray might provide clinically
useful information on patient survival.
Methods: Forty-three tumor tissues from 38 patients with stage III and stage IV melanoma were
profiled with a 17,500 element cDNA microarray. Expression data were analyzed using significance
analysis of microarrays (SAM) to identify genes associated with patient survival, and supervised
principal components (SPC) to determine survival prediction.
Results: SAM analysis revealed a set of 80 probes, corresponding to 70 genes, associated with
survival, i.e. 45 probes characterizing longer and 35 shorter survival times, respectively. These
transcripts were included in a survival prediction model designed using SPC and cross-validation
which allowed identifying 30 predicting probes out of the 80 associated with survival.
Conclusion: The longer-survival group of genes included those expressed in immune cells, both
innate and acquired, confirming the interplay between immunological mechanisms and the natural
history of melanoma. Genes linked to immune cells were totally lacking in the poor-survival group,
which was instead associated with a number of genes related to highly proliferative and invasive
tumor cells.
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Although cutaneous melanoma is a relatively rare tumor,
its incidence is rising sharply, with minimal progress
made in its treatment [1]. When lymph node or distant
metastases are present, clinical outcome is poor but highly
variable. In fact, patients in the same TNM stage can have
very different clinical outcomes, which is particularly true
for TNM stage III. Currently, the most useful prognostic
factors in metastatic disease are the metastatic site (e.g.
subcutaneous vs visceral localization) and lactate dehyro-
genase (LDH) plasma levels [2-4].
Despite significant efforts to identify independent predic-
tors of melanoma outcome, no generally accepted his-
topathological or molecular marker defines disease
subsets with clinically different outcomes [5-7]. Under-
standing differences in clinical behavior is important not
only in the design and analysis of clinical trials, but also
in planning different therapeutic strategies, such as adju-
vant treatment.
In recent years, microarray technology has been exten-
sively used in cancer research to obtain gene expression
profiles aimed at identifying tumor classes, disease-related
genes and new markers for predicting clinical outcome.
Several studies also demonstrated that gene expression
signatures can be used as a tool to predict survival of can-
cer patients [8-11]. As regards melanoma, analyses of gene
expression have shed new light on the progression from
local to metastatic disease as well as on melanoma
immune responsiveness [12-14].
In this study, we correlated the gene-expression profile of
tumors with overall survival in a cohort of patients with
stage III and IV melanoma to determine whether survival
among patients is reflected by specific sets of expressed
genes. By using the significance analysis of microarrays
(SAM), we identified 80 differentially expressed probes.
We also generated a survival prediction model that
resulted in 30 survival-related probes, all included in the
set identified by SAM.
Methods
Patients and tissue collection
From 1997 to 2000, we collected 43 fresh metastatic
melanoma biopsies from 38 patients with stage III and IV
melanoma who underwent surgery as a part of the diag-
nostic work-up or therapeutic strategy. For three of these
patients, we collected two biopsies, and in one case we
obtained three biopsies. Immediately after surgery, half
specimen was fixed in formalin and processed for routine
histology, and the other half was snap-frozen in liquid
nitrogen and stored at -80°C until use for RNA extraction.
This study was examined and approved by the Ethics
Committee of the local Health and Social Services
(Azienda Ospedaliera, Padova) in accordance with the
ethical standards laid down in the 1964 Declaration of
Helsinki.
RNA extraction, amplification and labeling
Total RNA was extracted from frozen material by homog-
enizing the sample in TRIZOL reagent (Invitrogen, CA),
according to the manufacturer's instructions, amplified
into anti-sense RNA (aRNA) and reverse transcribed into
fluorescent-labeled cDNA for hybridization to a custom-
made 17,500-gene cDNA-based array as previously
described [15,16]. After amplification, the quality of
aRNA was tested with the Agilent Bioanalyzer 2000 (Agi-
lent Technologies, Palo Alto, CA). Total RNA from periph-
eral blood mononuclear cells pooled from 6 normal
donors was extracted and amplified to prepare reference
aRNA to be cohybridized in all experiments with test
aRNA. cDNA targets were labeled with Cy3 for reference
material and Cy5 for test material. The 32 × 24 × 23
(17,500 spots) human cDNA microarray was prepared in
the Immunogenetics Section of Transfusion Medicine,
Clinical Center, National Institute of Health, Bethesda.
Clones for printing of 17 k cDNA array included a combi-
nation from a RG_HsKG_031901 7 k clone set and 10,000
clones from the RG_Hs_seq_ver_070700 40 k clone set
(Research Genetics, Huntsville, AL). The cDNA clones
include 12,072 uniquely named genes, 875 duplicates of
named genes; the remainder consisted of expression
sequence tags (complete gene list and printing layout are
available [17]. The hybridization was carried out at 65°C
for 16–18 hours, and the slides were then washed and
scanned on a Gene Pix 4000 scanner at variable PMT to
obtain optimized signal intensities with minimum (< 1%
spots) intensity saturation.
Statistical analysis
Before statistical analysis, data were loaded and filtered
using the software package BRB Array Tools [18]. Specifi-
cally, a statistical significance criterion based on the vari-
ance was used to filter log expression variations and
remove those genes whose expression log ratios did not
differ significantly from the median value (p-value ≤
0.01). Genes were also excluded if the percentage of miss-
ing expression values was greater than 50%, resulting in a
total of 4,845 probes used for further analysis.
Significance analysis of microarrays (SAM), [19,20] was
applied to identify genes correlated with patient overall
survival. Briefly, SAM computes a score for each gene that
measures the strength of transcript correlation with sur-
vival. This score is the maximum-likelihood score statistic
from Cox's proportional hazards model (Cox score). A
threshold value was chosen to give a reasonably low false
positive rate, as estimated by repeatedly permuting the
survival times and counting the number of genes thatPage 2 of 11
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dled using the K-nearest neighbors imputer (k = 10) of the
SAM imputation engine.
Survival prediction was calculated using supervised prin-
cipal components (SPC)[21]. This analysis is similar to
conventional principal component analysis although SPC
uses a subset of predictors that are selected based on their
association with outcome (see additional file 1 for a
detailed description).
SPC were applied using the R superpc package [22].
Immunohistochemistry
The following antibodies were used: HLA Class II (DR)
(Clone LN-3, Novocastra, Newcastle upon Tyne, UK, dilu-
tion 1:50) and IL-4R (clone 25463, R&D Systems, Abing-
don, UK).
Tissue sections of 4-µm were cut from formalin fixed, par-
affin-embedded tissue blocks and rehydrated. Endog-
enous peroxidase activity was blocked with incubation of
the slides in 3% H202 in methanol and then, primary anti-
bodies were applied at room temperature for 45 minutes.
Binding sites of the primary antibodies were visualized
using the Envision Plus detection System (Dako, Glos-
trup, Denmark) for HLA-DR and the Vectstain ABC kit
(Vector laboratories, Burlingame, USA) for IL-4R.
Sections were developed using 3-amino-9-ethylcarbazole
(Biogenex, San Ramon, USA), the slides were counter-
stained with hematoxylin and mounted in aqueous
medium.
Immunostaining for IL4R and HLA-DR was separately
evaluated in tumor cells and in intratumoral and peritu-
moral inflammatory cells and scored semi-quantitatively
as 0 (no staining), 1+ (0–25%), 2+ (26–50%), 3+ (>
50%).
Results
Patient Characteristics
The clinical and pathological characteristics of the 38
melanoma patients (20 females and 18 males) are
reported in Table 1. The median age at diagnosis was 58
years (range 23–82). Twenty-two (58%) patients had
stage III and 16 (42%) stage IV melanoma at the time of
biopsy. Two stage IV patients with subcutaneous and lung
metastases respectively were also affected by ocular
melanoma. Before biopsy, thirteen patients had been
treated: adjuvant interferon (adIFN) for 7 patients; sys-
temic chemotherapy (Sy-CT) for 2 patients; Sy-Ct and
adIFN in 1 case; isolated hyperthermic perfusion (HIP) in
1 case; adIFN, Sy-CT and HIP in 1 case; and Sy-CT and
radiotherapy in another patient. After a median follow-up
of 65 months (range 48–103), 9 patients (7 females and
2 males) were still alive without clinical evidence of dis-
ease. Twenty-nine patients (76%) died as a consequence
of the melanoma progression; 7 of whom of brain metas-
tases (24%).
Identification of a gene set correlated with survival
Using nucleotide arrays, we generated gene-expression
profiles for 43 metastatic melanomas by analyzing 30
metastatic lymph-nodes, 11 cutaneous, 1 lung and 1 gas-
trointestinal metastases [15,16]. To identify a gene expres-
sion profile correlated with overall survival, we used SAM
class comparison. This method identified a total of 80
probes (Tables 2 and 3) corresponding to 70 unique genes
associated with survival, 45 negatively (Table 2) and 35
positively (Table 3), with a median of 13.06 false positive
(q-value < 15%) selecting ∆ = 0.36 and 500 random per-
mutations. The value of ∆ was selected as a compromise
between the total number of significant probes and the
false positive rate. When the score is negative, higher
expression correlates with longer survival, whereas a pos-
itive score indicates that higher expression correlates with
shorter survival. The expression pattern of the 80 probes
identified by SAM as related to survival in the 43 samples
is shown in the dendrogram of Fig. 1. In this analysis stage
III and stage IV patients are equally distributed among the
2 groups with significantly different survival times (data
not shown), clearly indicating that our study group did
not have a selection bias.
DNA microarray technology allows for the development
of predictive models using gene expression profiles to
Table 1: Clinical characteristics of the 38 patients with 
melanoma considered in the present study.
Characteristic Patients (N = 38)
Gender # %
Male 18 47
Female 20 53
Age
Median 58
Range 23–82
Stage III* 22 58
Stage IV* 16 42
Previous Treatment**
No 25 66
Yes** 13 34
Interferon*** 9 69
Chemotherapy 5 38
Isolated Perfusion 2 15
Radiotherapy 1 7
* According the new AJCC staging system for melanoma [3]
** Some patients received more than one treatment
*** Alone or in combination with chemotherapyPage 3 of 11
(page number not for citation purposes)
Journal of Translational Medicine 2006, 4:50 http://www.translational-medicine.com/content/4/1/50
Page 4 of 11
(page number not for citation purposes)
Table 2: Top 45probes whose increase in expression is significantly associated with longer survival.
Feature ID Gene symbol Gene name
IMAGE:128126 DAF Decay accelerating factor for complement
IMAGE:504226 CD53 CD53 antigen
IMAGE:66560 IGLC2 immunoglobulin lambda locus
IMAGE:770670 TNFAIP3 Tumor necrosis factor, alpha-induced protein 3
IMAGE:153411 HLA-DRA Major histocompatibility complex, class II, DR alpha
IMAGE:767183 HCLS1 Haematopoietic cell-specific Lyn substrate 1
IMAGE:344134 IGLL1 Immunoglobulin lambda-like polypeptide 1
IMAGE:2448698 HLA-DRB4 major histocompatibility complex, class II, DR beta 4
IMAGE:2443695 HLA-DRB4 major histocompatibility complex, class II, DR beta 4
IMAGE:897641 HNRPU Heterogeneous nuclear ribonucleoprotein U
IMAGE:210921 NFKBIZ Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, zeta
IMAGE:141806 TNFAIP3 Tumor necrosis factor, alpha-induced protein 3
IMAGE:1572582 NCF4 Neutrophil cytosolic factor 4, 40 kDa
IMAGE:2508563 TNFAIP3 Tumor necrosis factor, alpha-induced protein 3
P48460 LTB lymphotoxin beta (TNF superfamily, member 3)
IMAGE:714453 IL4R IL-4 receptor alpha chain
IMAGE:1469292 PIM2 Pim-2 oncogene
IMAGE:2443532 SVIL Supervillin
IMAGE:1585327 AXIN2 Axin 2 (conductin, axil)
IMAGE:814802 Similar to serine/threonine kinase 4
IMAGE:2512080 CST1 Cystatin SN
IMAGE:827132 RAC2 Ras-related C3 otulinum toxin substrate 2
IMAGE:309864 JUNB Jun B proto-oncogene
IMAGE:293925 LYZ Lysozyme
IMAGE:789314 CD1D CD1D antigen, d polypeptide
IMAGE:246748 BTK Bruton agammaglobulinemia tyrosine kinase
IMAGE:295868 LAPTM5 Lysosomal associated multispanning membrane protein 5
IMAGE:199334 C14orf117 chromosome 14 open reading frame 117
IMAGE:50877 LOC91316 similar to bK246H3.1 (immunoglobulin lambda-like polypeptide 1, pre-B-cell specific)
IMAGE:346860 SOD2 Superoxide dismutase 2, mitochondrial
IMAGE:727988 CDW52 CD52 antigen
IMAGE:320393 HLA-DQA1 Major histocompatibility complex, class II, DQ alpha 1
IMAGE:2010319 NALP1 NACHT, leucine rich repeat and PYD (pyrin domain) containing 1
IMAGE:243741 UBD Ubiquitin D
IMAGE:868368 TMSB4X Thymosin, beta 4, X-linked
IMAGE:1552744 CD2 CD2 antigen (p50)
IMAGE:855547 HLA-DRB1 major histocompatibility complex, class II, DR beta 1
IMAGE:342378 DUSP5 Dual specificity phosphatase 5
IMAGE:823779 PLEK Pleckstrin
IMAGE:2562146 MAPK13 Mitogen-activated protein kinase 13
IMAGE:682418 ELF4 E74-like factor 4
IMAGE:712209 ARHGAP15 Rho GTPase activating protein 15
IMAGE:770014 TRA@ T cell receptor alpha chain
IMAGE:2281706 ITK IL2-inducible T-cell kinase
IMAGE:428412 GZMK Granzyme K
Journal of Translational Medicine 2006, 4:50 http://www.translational-medicine.com/content/4/1/50study the relationship between prognosis and molecular
features of the tumor. New statistical methods have been
developed to address high dimensionality and low sam-
ple size issues characterizing microarray data [21,23,24].
To predict survival in this group of melanoma patients, we
applied SPC, a survival prediction model that was
designed and validated using a leave-one-out cross-valida-
tion procedure [21]. Specifically, the model has been con-
structed applying the singular value decomposition
procedure to the matrix X' consisting of only those genes
whose Cox scores are greater than some threshold θ
whose optimal value has been determined through a
leave-one-out cross-validation procedure. In details, start-
ing from a set G of possible values of θ, for each θ in G,
one sample is left out, and those genes with absolute Cox
scores greater than θ in the other n-1 samples are used to
calculate  for the left out sample. A Cox proportional
hazards model is then fit to  (i.e., to the first supervised
principal component of ) and the chi-square statistic
for the log-rank test associated with this model calculated.
The procedure is repeated for each value of θ and any sam-
ple in the dataset. The overall likelihood ratio test indi-
cated that the association between left-out samples and
the supervised predictor constructed on  is optimized at
a value of θ = 1.7 at a p-value = 0.0002 (Supplementary
Fig. S1). Thus, the survival prediction model has been
constructed using the first principal component of those
genes having a Cox score greater than 1.7 and resulted in
30 survival-related probes (Fig. 1, in black the transcripts
used to build the SPC survival predictor).
Fig. 2, panel A illustrates the survival probability of the 43
samples, grouped according to the median value of  =Vˆ
vˆ1
Vˆ
vˆ1
vˆ1
30
Table 3: Top 35 probes whose increase in expression is significantly associated with shorter survival.
Feature ID Gene symbol Gene name
IMAGE:809557 MCM3 MCM3 minichromosome maintenance deficient 3
IMAGE:823859 GJB2 Gap junction protein, beta 2, 26 kDa (connexin 26)
IMAGE:505573 PYGL Phosphorylase, glycogen; liver
IMAGE:626544 MYO10 Myosin X
IMAGE:2488304 TRIM32 Tripartite motif-containing 32
IMAGE:200402 C20orf129 Chromosome 20 open reading frame 129
IMAGE:269791 DCT Dopachrome tautomerase (tyrosine-related protein 2)
IMAGE:2297394 EFHD1 EF-hand domain family, member D1
P07338 CSPG4 Chondroitin sulfate proteoglycan 4 (melanoma-associated)
IMAGE:897563 M-RIP Myosin phosphatase-Rho interacting protein
IMAGE:504461 KMO&OPN3* Kynurenine 3-monooxygenase & Opsin 3*
IMAGE:768571 SOX8 SRY (sex determining region Y)-box 8
IMAGE:138601 KIAA1026 Kazrin
IMAGE:626544 MYO10 Myosin X
IMAGE:1461664 BCHE Butyrylcholinesterase
IMAGE:365826 GAS1 Growth arrest-specific 1
IMAGE:486175 SLC16A1 Solute carrier family 16, member 1
IMAGE:823886 MYH10 Myosin, heavy polypeptide 10, non-muscle
IMAGE:866882 FDFT1 Farnesyl-diphosphate farnesyltransferase 1
IMAGE:592802 RGS12 Regulator of G-protein signalling 12
IMAGE:815151 PRKCE Protein kinase C, epsilon
IMAGE:2049072 ADAMTS5 A disintegrin-like and metalloprotease with thrombospondin type 1 motif, 5
IMAGE:811562 NEO1 Neogenin homolog 1 (chicken)
IMAGE:241705 PYGL Phosphorylase, glycogen; liver
IMAGE:143919 CHEK1 CHK1 checkpoint homolog
IMAGE:811562 NEO1 Neogenin homolog 1 (chicken)
IMAGE:503889 P15RS Hypothetical protein FLJ10656
IMAGE:504461 KMO&OPN3* Kynurenine 3-monooxygenase & Opsin 3*
IMAGE:266263 cDNA FLJ31683 fis
IMAGE:269733 BNC2 Basonuclin 2
IMAGE:486561 PARVA Parvin, alpha
IMAGE:453599 C14orf109 Chromosome 14 open reading frame 109
IMAGE:38925 EST EST, Weakly similar to S10889 proline-rich protein
IMAGE:824776 DHFR Dihydrofolate reductase
IMAGE:2018084 STK39 Serine threonine kinase 39
*Clone IMAGE:504461 maps to 2 Unigene ClustersPage 5 of 11
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Supervised hierarchical representation of the 80 probes selected by SAM and related to survival probabilityFigu e 1
Supervised hierarchical representation of the 80 probes selected by SAM and related to survival probability. In 
blue the 80 probes selected by SAM and in black the 30 transcripts used to build the SPC survival predictor. Samples are 
labeled according to survival probability curves of Figure 2 (solid and dotted line for shorter and longer survival, respectively) 
and Martingale residuals of the null model are reported for each specimen. The Martingale residuals represent the difference 
between the observed and expected number of events for each individual. Thus, large negative residuals indicate that the 
observed number of deaths is less than the expected number of deaths, i.e. the individual lived longer than expected. Large 
positive residuals (closed to 1) indicate that the observed number of deaths is greater than the expected number of deaths, i.e. 
the individual's survival time was shorter than expected.
Journal of Translational Medicine 2006, 4:50 http://www.translational-medicine.com/content/4/1/50 (θ = 1.7), i.e., the predicted values obtained selecting
the first 30 probes corresponding to the threshold θ = 1.7,
with short and long survivors having a value of  higher
and lower than the median, respectively.
Although these 30 predicting probes are all among the 80
transcript identified by SAM as associated to survival (Fig.
1), it has to be noted that class predictors constructed
using a small number of variables may heavily depend on
any one variable and produce spuriously high prediction
strengths. However, the cross-validated predictor can also
be constructed using a large number of transcripts without
loosing statistical significance. Indeed, the overall likeli-
hood ratio test indicates that the association between left-
out samples and supervised predictor constructed on  is
still significant (p-value < 5%) for lower values of the
threshold θ . As an examples, selecting a value of θ = 0.6
resulted in 1500 predicting probes which partitioned the
samples according to the predicted survival curves of Fig.
2, panel B (  =  (θ = 0.6)).
To adjust for prognostic factors, we also applied a multi-
dimensional Cox model where the predicted value of the
first principal component obtained by SPC using the first
30 and 1,500 probes (e.g.,  and ) has been ana-
lyzed together with other prognostic factors, such as LDH
plasma level and the number of metastases. Results from
this multidimensional analysis indicate that the transcrip-
tional patterns are significantly associated with survival
time (p-value = 0.02 for  and p-value = 0.06 for )
also in the presence of other prognostic factors. On the
contrary, LDH and the number of metastasis did not result
statistically correlated with survival (p-value = 0.16 and p-
value = 0.21 for LDH and p-value = 0.87 and p-value =
0.91 for number of metastasis considering  and ,
respectively).
Validation of microarray data
We validated at the protein level by immunohistochemis-
try (IHC) the results obtained from gene expression anal-
ysis. Of the first 80 probes, 5 coded for HLA class II
molecules, which are constitutively expressed on antigen
presenting cells and B cells, on non-immune cell types
under inflammatory conditions and by melanoma cells
[25,26]. Although we selected for microarray analysis
melanoma biopsies that had a high percentage of tumor
cells, the contribution of genes expressed at low level by
cells present in tumor infiltrate cannot be ruled out. More-
over, 30 of 43 biopsies were infiltrated metastatic lymph
nodes and thus a small amount of residual lymphoid tis-
sue, expressing HLA class II molecules, could have been
present.
To assess if the expression of HLA class II molecules corre-
lating with longer survival was due to melanoma cells or
to other cells in the infiltrate, we verified by IHC the
expression of these proteins with an antibody directed
vˆ1
vˆ1
30
vˆ1
vˆ1
1500 vˆ1
vˆ1
30 vˆ1
1500
vˆ1
30 vˆ1
1500
vˆ1
30 vˆ1
1500Survival probability of the 43 samplesFigure 2
Survival probability of the 43 samples. A) Prediction 
was based on the  model using 30 transcripts with θ = 1.7 
( ). Dotted and solid curves represent samples with  
higher and lower than median , respectively. Log-rank-p-
value= 0.000127. B) The curves represent the predicted sur-
vival for patients obtained using different values of v1 (esti-
mated using the first 1500 genes), i.e., the 10th (0.044), 25th 
(0.215), 50th (0.280), 75th (0.428), and 90th (0.563) percentiles 
of v1.
vˆ1
vˆ1
30 vˆ1
30
vˆ1Page 7 of 11
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of 43 melanoma biopsies for which corresponding paraf-
fin-embedded specimens were available. HLA-DR expres-
sion was found on melanoma cells in 7 of 33 samples
(Fig. 3 and Table 4), mainly with focal staining, while in
the majority of cases (30/33) positivity was detected in the
inflammatory cells that infiltrated melanoma deposits.
On the other hand, a closer analysis of the two patient
groups with significantly different survival lengths (as
identified by SAM analysis) disclosed that HLA-DR
expression was higher in melanoma cells of patients with
longer survival than in those with shorter survival time (6
samples vs 1 sample, Table 4), while it was almost equally
represented in the inflammatory cells of the two groups of
patients.
Up-regulation of HLA class II molecules can be induced
by a number of molecules, including IL-4. This study dem-
onstrated that increased expression of the IL-4R alpha
chain gene was correlated with longer survival (Table 2).
To confirm this finding, we investigated the presence of
this protein in all available tumor biopsies by IHC. In 11
of 27 lesions, tumor cells expressed IL-4R (Fig. 3), while
in 6 lesions a heterogeneous positive staining was
observed also on inflammatory cells permeating the neo-
plasia (Table 4). Combining the staining on tumor and
infiltrating cells, a higher incidence of IL-4R positive
lesions was observed in patients with longer survival,
therefore confirming the findings of the transcriptional
analysis (Table 4).
CD4 and CD8 staining also revealed the presence of a
mild to moderate T cell infiltrate inside melanoma cell
nests in the majority of cases; usually intratumoral CD4+
and CD8+ T cells were co-localized within the lesion (data
not shown).
Association of the selected genes with survival
Eighty probes identified by SAM consisted of 40 genes
whose increased expression was associated with longer
survival, and 30 genes whose increased expression was
associated with shorter survival. Genes involved in
immune response and inflammation such as HLA class II,
TRA@, LTB, TNFAIP3, IL-4R, IGLL1, CD1D, CD2, ITK,
SOD2, DAF and GZMK, were associated selectively with
longer survival, confirming once more the important
interplay between the host immune system and malig-
nant cells in melanoma.
Conversely, analysis of tumor progression-associated
genes revealed an increased expression of those impli-
cated in cell adhesion, motility and proliferation. For
example, gene GJB2, encoding the gap junction protein
connexin 26 (Cx26) a sub-type of gap junction proteins;
gene CSPG4, coding for the melanoma-associated chon-
droitin sulfate proteoglycan 4; the disintegrin-like and
metalloprotease genes with thrombospondin type 1
(ADAMTS5); the minichromosome maintenance 3
(MCM3) and the DCT genes, all whose expression by
tumor cells is frequently associated with more invasive
and metastatic behavior [27-33].
Discussion
In this study, we used gene expression profiling and sur-
vival data from advanced melanoma patients and, by SAM
class comparison, identified a set of 80 probes, corre-
Immunohistochemical analysisFigure 3
Immunohistochemical analysis. Representative sections of a melanoma biopsy immunostained with anti-HLA-DR (left 
panel, 20×), and anti-IL4R mAbs (right panel, 20×).Page 8 of 11
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vival-associated group of genes highlighted characteristics
of melanoma cells, but also of non-malignant cells
present in the tumor tissue. In fact, while specimens were
selected on the basis of histological diagnosis, and charac-
terized by a high proportion of neoplastic tissue, the use
of whole tumor tissue enabled us to detect changes in
gene expression associated with stromal and infiltrating
immune/inflammatory cells.
Five of the probes selected using SAM encode HLA class II
molecules. This MHC class II signature has already been
associated with a favorable outcome in patients with large
B-cell lymphoma [11], while in the liver microenviron-
ment HLA class II overexpression is associated with a
metastasis-inclined phenotype [34], suggesting that the
prognostic genes may differ among different tumor types.
In human melanoma, the association of these molecules
with survival is controversial. Some authors reported that
enhanced HLA class II expression was associated with an
unfavorable prognosis [25,35], while others found a pos-
itive correlation with overall survival [36,37]. Our data are
in line with the latter findings and the IHC analysis con-
firmed that the expression of these molecules in the
melanoma cells was almost exclusively associated with
longer survival (Table 4). CD4+ and CD8+ cells were found
in the same lesions, and, as reported by others, a close cor-
relation between MHC class II expression and presence of
T cells was observed (data not shown). This phenomenon
may be the result of an inflammatory process at the tumor
site in which the cytokines released, such as IFN and TNF,
induce MHC class II up-regulation. IL-4 may also be pro-
duced in an inflammatory milieu, and can up-regulate the
expression of these molecules [38]. It has already been
shown that melanoma cells may express IL-4 receptors
and that IL-4 has antiproliferative and/or apoptotic effects
in these cells [39]. Interestingly, the gene for the IL-4R
alpha chain was included in the longer-survival set of
genes, suggesting that its presence might be related to
these cytotoxic pathways. As predicted by SAM, IHC
revealed a positive staining for IL-4R, confirming at the
protein level that enhanced expression was more evident
in patients with longer survival (Table 4). IHC studies
indicated also that IL-4R staining was localized in
melanoma cells, as well as in interstitial inflammatory
cells and in residual lymphoid tissue. Despite the intrinsic
limitations of this study, these findings highlight the role
of CD4+ T-lymphocytes in the anti-melanoma immune
response. Interestingly, the CD4 probe was among the
first 225 probes selected by SAM, while the probe for CD8
was not included in the list of the first 3,000 differentially
expressed genes.
The role of the immune system in survival of metastatic
melanoma patients is also evident when other genes are
considered. In addition to the MHC class II genes, other
genes associated with survival direct the anti-tumor activ-
ity exerted by effector cells of the immune system such as
T cells (TRA@, GZMK), NKT cells (CD1d) and B cells
(IGLC2), confirming the notion that the clinical course of
melanoma is closely associated with innate and acquired
immune responses. It is of interest that genes known to be
involved in the immune response were present exclusively
in the longer-survival group, thus confirming an immune-
response signature associated with favorable prognosis.
The finding that genes associated with immune cell activa-
tion are part of the molecular signature that herald a good
prognosis in stage III and IV melanoma patients is remark-
able, since it highlights, at a molecular level, the potential
efficacy of the immune response also in advanced
melanoma. Thus, melanoma survival is associated not
only with the intrinsic biology of tumor cells, but also
with an efficient immune response that encompasses dif-
ferent facets of the immune system.
Of the genes correlated with shorter survival, some were
already known to be over-expressed in different types of
cancer, such as MCM3, BCHE [32,40-42], and some have
Table 4: HLA-DR and IL4R expression determined by IHC as graded by the scoring system (1+ to 3+).
Antigen Patients with shorter survival Patients with longer survival
Scoring # of patients Scoring # of patients
0 1+ 2+ 3+ 0 1+ 2+ 3+
HLA-DR 17 16
tumor cells 16 1 0 0 10 5 0 1
non tumor cells* 2 2 10 3 1 6 5 4
IL4R 14 13
tumor cells 9 3 2 0 7 5 0 1
non tumor cells* 13 1 0 0 8 3 2 0
* lymphoid tissue and inflammatory interstitial cellsPage 9 of 11
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like CSPG4 [43] and Cx26 [28] or, more generally, associ-
ated with tumor invasiveness, like ADAMTS5 [31].
The survival prediction model, designed using SPC, iden-
tified 30 survival-related probes, which were all among
the 80 probes identified by SAM. Although we have not
yet tested this predictive model on an independent series
of patients, the results of the cross-validation were quite
encouraging. Identifying a subset of genes that predict
cancer patients' survival is an important goal of microar-
ray research since it could ultimately lead to the develop-
ment of prognostic tools that, by identifying patients with
different clinical outcome, might lead to tailor therapeutic
strategies on a single patient basis. This might be particu-
larly relevant for patients with stage III melanoma, as the
lack of definitively convincing results on interferon-alpha
based adjuvant treatment might depend upon inadequate
patient selection [44].
Conclusion
In conclusion, this study applied high-throughput gene
microarrays to screen the transcriptome in the search for
genes correlated with patient survival. The bioinformatics
data analysis allowed us to identify a number of genes
related to cell proliferation and invasiveness that enable
tumor cells to progress to a more aggressive phenotype. If
validated by subsequent independent studies, these genes
might serve as predictors of survival, and thus help clini-
cians to identify patients at higher risk of disease progres-
sion. Moreover, the transcripts associated to the longer-
survival group included genes expressed in immune cells,
both innate and acquired, confirming the importance of
the interplay between immunological surveillance and
the natural history of melanoma. These results highlight
how critical the relationship is between melanoma cell
aggressiveness and the activity of innate and/or acquired
immune cells for the ultimate tumor outcome.
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